EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Performance of Elecsys® HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection

Prooksa Ananchuensook iD, Jongkonnee Wongpiyabovorn, Anchalee Avihingsanon iD, Pisit Tangkijvanich iD

Diagnostics · 29.09.2024 · 14 (19) · 2179

DOI: 10.3390/diagnostics14192179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 29.09.2024. Verfasst von Prooksa Ananchuensook und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research received funding support from the NSRF via the Program Management Unit for Human Resources & Institutional Development, Research and Innovation (…, NSRF, Thailand Science Research and Innovation (TSRI) via Chulalongkorn University, and Roche Thailand Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The Elecsys® HCV Duo immunoassay (Roche Diagnostics International Ltd., Rotkreuz, Switzerland) detects both antibodies to hepatitis C virus (anti-HCV) and HCV core antigen (HCV-Ag) and has shown excellent diagnostic performance in blood donor samples. We aim to validate its use for diagnosing chronic HCV infection and assessing sustained virological response (SVR) post-direct-acting antivirals (DAAs) in patients with or without HIV infection.

Methods

Blood samples from 100 healthy controls, as well as 64 HCV mono-infection and 136 HCV-HIV coinfections, were collected before and 12–24 weeks after DAAs. The assay performance for determining active infection at baseline and SVR was compared with HCV RNA.

Results

Overall, 156 (78.0%) of HCV-infected patients had HCV genotype 1, and the SVR rate was 96.5%. The sensitivity, specificity, and area under the ROC curve (AUROC) for HCV diagnosis at baseline were 99.50% (95% confidence interval [CI], 96.82–99.97%), 100% (95%CI, 95.39–100%), and 0.998 (95%CI, 0.992–1.003), respectively. The corresponding results for HCV-Ag in determining SVR were 57.14% (95%CI, 20.24–88.19%), 97.41% (95%CI, 93.73–99.04%), and 0.773 (95%CI, 0.543–1.003), respectively. The assay also exhibited comparable sensitivity and specificity between HCV mono- and coinfection.

Conclusions

Our study showed that the Elecsys® HCV Duo immunoassay effectively diagnosed HCV infection, regardless of HIV status, making it suitable for managing high-risk populations in resource-limited settings.

Schlagwörter

Stichwörter der Autor:innen

Elecsys® HCV Duo immunoassayHCV antibodiesHCV core antigenchronic hepatitis C virus (HCV) infectiondirect-acting antivirals (DAAs)sustainedvirological response (SVR)

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
  • Academic Affair, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
  • Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
  • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok 10330, Thailand.
  • Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, Chulalongkorn University, Bangkok 10330, Thailand.

ORCID-Profile: Prooksa Ananchuensook, Anchalee Avihingsanon, Pisit Tangkijvanich

Förderung

  • This research received funding support from the NSRF via the Program Management Unit for Human Resources & Institutional Development, Research and Innovation (…
  • NSRF
  • Thailand Science Research and Innovation (TSRI) via Chulalongkorn University, and Roche Thailand Ltd.

Zitieren

APA

Ananchuensook, P., Wongpiyabovorn, J., Avihingsanon, A., & Tangkijvanich, P. (2024). Performance of Elecsys® HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection. Diagnostics, 14(19), 2179. https://doi.org/10.3390/diagnostics14192179

Vancouver

Ananchuensook P, Wongpiyabovorn J, Avihingsanon A, Tangkijvanich P. Performance of Elecsys® HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection. Diagnostics. 2024;14(19):2179. doi:10.3390/diagnostics14192179

BibTeX
@article{Ananchuensook2024,
  author = {Ananchuensook, Prooksa and Wongpiyabovorn, Jongkonnee and Avihingsanon, Anchalee and Tangkijvanich, Pisit},
  title = {Performance of Elecsys® HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection},
  journal = {Diagnostics},
  year = {2024},
  volume = {14},
  number = {19},
  pages = {2179},
  doi = {10.3390/diagnostics14192179}
}
Kostenlos starten →